SG Americas Securities LLC bought a new stake in C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) during the third quarter, Holdings Channel reports. The fund bought 24,941 shares of the company’s stock, valued at approximately $142,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of C4 Therapeutics in the 1st quarter worth about $339,000. Susquehanna Fundamental Investments LLC acquired a new position in C4 Therapeutics during the first quarter valued at approximately $420,000. Entropy Technologies LP purchased a new stake in C4 Therapeutics during the first quarter worth approximately $126,000. Vanguard Group Inc. increased its position in shares of C4 Therapeutics by 46.0% in the first quarter. Vanguard Group Inc. now owns 2,920,028 shares of the company’s stock worth $23,857,000 after acquiring an additional 920,627 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in shares of C4 Therapeutics in the 1st quarter valued at $233,000. Hedge funds and other institutional investors own 78.81% of the company’s stock.
C4 Therapeutics Stock Down 1.0 %
CCCC opened at $5.89 on Friday. The firm’s 50 day moving average is $6.06 and its 200-day moving average is $5.88. C4 Therapeutics, Inc. has a 52-week low of $1.06 and a 52-week high of $11.88. The firm has a market capitalization of $405.27 million, a P/E ratio of -2.49 and a beta of 3.04.
Analysts Set New Price Targets
Separately, BMO Capital Markets reaffirmed an “outperform” rating and set a $20.00 price target on shares of C4 Therapeutics in a research report on Tuesday, August 6th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.50.
Read Our Latest Analysis on C4 Therapeutics
About C4 Therapeutics
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Featured Stories
- Five stocks we like better than C4 Therapeutics
- The Most Important Warren Buffett Stock for Investors: His Own
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the Nikkei 225 index?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding CCCC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report).
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.